Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus
Efsitora caused an immunogenic response in up to 3.0% of participants with T1DM and T2DM. Descriptive analysis indicates that the immunogenicity of efsitora did not noticeably impact its pharmacokinetics, efficacy or safety. The molecular design of efsitora may contribute to its low immunogenicity.
Authors
- Michelle L. Katz (ORCID: https://orcid.org/0000-0002-5441-5071)
- Robert J. Konrad (ORCID: https://orcid.org/0000-0003-0923-0542)
- Vitoria Pires
- Sihe Wang (ORCID: https://orcid.org/0000-0001-5423-8303)
- Jennifer Leohr (ORCID: https://orcid.org/0000-0001-5434-7905)
- Christopher J. Child (ORCID: https://orcid.org/0000-0002-6195-2780)
- Yun Wang (ORCID: https://orcid.org/0000-0003-3117-8955)
- Xiaoqi Li (ORCID: https://orcid.org/0000-0001-7200-2134)
- Wei J. Wang (ORCID: https://orcid.org/0000-0002-4848-7394)
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1111/dom.70325
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00